Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome

Summary

The antiphospholipid syndrome (APS) refers to persistent antiphospholipid antibodies (aPL) associated with thrombotic and/or obstetrical complications. The endothelial cell is a target of aPL which can induce a procoagulant and proinflammatory endothelial phenotype, as reported both in vivo and in vitro. Microparticle production is a hallmark of cell activation. In the present study, the presence of endothelial microparticles (EMP) in the plasma of APS patients was investigated. To determine if there is a correlation with certain biological and clinical features, EMP levels were measured in thrombosis-free patients with systemic lupus erythematosus (SLE) patients, with and without aPL, in patients with non aPL-related thrombosis, as well as in healthy controls. Compared to healthy subjects, elevated plasma levels of EMP were found in patients with APS and in SLE patients with aPL, but not in SLE patients without aPL or in non aPL-related thrombosis. EMP levels were also associated with Lupus Anticoagulant (LA) detected by a positive Dilute Russell’s Viper Venom time (DRVVT). In parallel, we analyzed the capacity of these plasma to induce vesiculation of cultured endothelial cells. We demonstrated an increase of EMP generated in response to plasma from patients with autoimmune diseases. Interestingly, only APS plasma induced the release of EMP with procoagulant activity. These ex vivo and in vitro observations indicate that generation of EMP in APS and SLE patients results from an autoimmune process involving aPL. Production of procoagulant microparticles in APS patients may represent a new pathogenic mechanism for the thrombotic complications of this disease.

Keywords

Antiphospholipid syndrome - microparticles - procoagulant activity

• References

• 1 Harris EN, Hughes GR, Gharavi AE. Antiphospholipid antibodies: an elderly statesman Dons new garments. J Rheumatol 1987; 14 (Suppl. 13) 208-13.
• 2 Field SL, Brighton TA, McNeil HP. et al.. Recent insights into antiphospholipid antibody-mediated thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12: 407-22.
• 3 George J, Blank M, Levy Y. et al.. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998; 97: 900-6.
• 4 Gharavi AE, Pierangeli SS, Espinola RG. et al.. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46: 545-52.
• 5 Ziporen L, Blank M, Shoenfeld Y. Animal models for antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 1997; 23: 99-117.
• 6 Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994; 03: 247-51.
• 7 Pierangeli SS, Liu XW, Barker JH. et al.. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995; 74: 1361-7.
• 8 Wilson WA, Gharavi AE, Koike T. et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (07) 1309-11.
• 9 Atsumi T, Khamashta MA, Amengual O. et al.. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77: 222-3.
• 10 Amengual O, Atsumi T, Khamashta MA. et al.. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-81.
• 11 Roubey RA. Tissue factor pathway and the antiphospholipid syndrome. J Autoimmun 2000; 15: 217-20.
• 12 Kaplanski G, Cacoub P, Farnarier C. et al.. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome – Correlations with the severity of thrombosis. Arthritis Rheum 2000; 43: 55-64.
• 13 Simantov R, Lasala JM, Lo SK. et al.. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-19.
• 14 Hanly JG, Hong C, Issekutz A. Beta 2-glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells. J Rheumatol 1996; 23: 1543-49.
• 15 Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-10.
• 16 Kornberg A, Renaudineau Y, Blank M. et al.. Anti-beta 2-glycoprotein I antibodies and antiendothelial cell antibodies induce tissue factor in endothelial cells. Isr Med Assoc J 2000; Suppl: 27-31.
• 17 Nakamura N, Ban T, Yamaji K. et al.. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset. J Clin Invest 1998; 101: 1951-9.
• 18 Bevers EM, Comfurius P, Dekkers DW. et al.. Transmembrane phospholipid distribution in blood cells: control mechanism and pathophysiological significance. J Biol Chem 1998; 379: 973-86.
• 19 Barry OP, Pratico D, Lawson JA. et al.. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-27.
• 20 Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. J Immunol 1998; 16: 4382-7.
• 21 Combes V, Simon AC, Grau GE. et al.. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
• 22 Sabatier F, Roux V, Anfosso F. et al.. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factordependent procoagulant activity. Blood 2002; Jun 1; 99 (11) 3962-70.
• 23 Nieuwland R, Berckmans RJ, McGregor S. et al.. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-5.
• 24 Joop K, Berckmans RJ, Nieuwland R. et al.. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85: 810-20.
• 25 Jimenez JJ, Jy W, Mauro LM. et al.. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Brit J Haematol 2001; 112: 81-90.
• 26 Minagar A, Jy W, Jimenez JJ. et al.. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001; 56: 1319-24.
• 27 Mallat Z, Benamer H, Hugel B. et al.. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-43.
• 28 Harris EN, Baguley E, Asherson RA. et al.. Clinical and serological features of the “antiphospholipid syndrome”. Br J Rheumatol 1987; 26 (Suppl. 02) 19-25.
• 29 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-31.
• 30 Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-603.
• 31 Verrot D, Sanmarco M, Dravet C. et al.. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103: 33-37.
• 32 Galli M. Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome?. Haemostasis 2000; 30 (Suppl. 02) 57-62.
• 33 Ames PR, Pyke S, Iannaccone L. et al.. Antiphospholipid antibodies, haemostatic variables and thrombosis – a survey of 144 patients. Thromb Haemost 1995; 73: 768-73.
• 34 Horbach DA, van Oort E, Donders RC. et al.. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
• 35 Bijl M, Limburg PC, Kallenberg CG. New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. Neth J Med 2001; 59 (02) 66-75.
• 36 Beutler B, Bazzoni F. TNF, apoptosis and autoimmunity: A common thread?. Blood Cells Molecules Dis 1998; 24: 216-30.
• 37 Hamilton KK, Hattori R, Esmon CT. et al.. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-14.
• 38 Andrade F, Casciola-Rosen L, Rosen A. Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 2000; 26: 215-27.
• 39 Rauch J, Subang R, D’Agnillo P. et al.. Apoptosis and the antiphospholipid syndrome. J Autoimmun 2000; 15: 231-35.
• 40 Del Papa N, Raschi E, Catelli L. et al.. Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. Am J Reprod Immunol 1997; 38: 212-7.
• 41 George J, Blank M, Levy Y. et al.. Differential effects of anti-beta(2)-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998; 97: 900-6.
• 42 Lieby P, Soley A, Levallois H. et al.. The clonal analysis of anticardiolipin antibodies in a single patient with primary antiphospholipid syndrome reveals an extreme antibody heterogeneity. Blood 2001; 97: 3820-8.